Stock Surge Signals the Dawn of Commercialization for Brain-Computer Interfaces?

At the beginning of 2026, Musk brought a new surprise to the global capital market.

On January 1, he announced on social media that Neuralink's brain-computer interface device would enter mass production within the year, and a streamlined, highly automated surgical procedure would be advanced. This news was akin to pressing the "fast-forward" button for the commercial implementation of brain-computer interfaces.

The feverish sentiment quickly spread to the market, with Neuralink's popularity skyrocketing and Regencell Bioscience Holdings' stock price surging 60% in just two days. On the first trading day in China's A-share market across the ocean, the brain-computer interface sector exploded with a 13.7% surge. Dozens of related stocks, including Neuracle, Bayi Healthcare, Better Medical, and Biotron Diagnostics, collectively hit the daily limit-up, as tens of billions of yuan poured in.

All of a sudden, the concept of brain-computer interface, which has been explored in labs for half a century, was pushed to the altar by capital and media. But behind this wave of excitement, whether 2026 will be the singularity year for the brain-computer interface industry to take off or another overestimated tech bubble still remains to be evaluated.

| Market Value Continues to Rise, Sci-Fi Concepts About to Be Realized? |

The craze around brain-computer interfaces is not baseless hype, but rather a resonance triggered by breakthroughs in top-tier technology, national strategic support, and strong market expectations.

Musk and his Neuralink are undoubtedly the initiators of this "party". He not only announced the commercial milestone for mass production but also described a "conveyor-belt-style" fully automatic minimally invasive surgery, which contains disruptive technological innovation.

Through the development of flexible electrodes and the exploration of robotic surgery, Neuralink has compressed the originally hours-long, high-risk craniotomy procedure to about 30 minutes. Moreover, the operation process does not require cutting open the dura mater, significantly reducing surgical trauma, infection risks, and costs, fundamentally addressing the core challenges of commercializing invasive brain-computer interfaces.

If Neuralink's technological breakthrough is the "spark," then China's deep industrial foundation and clear national will have provided ample "dry wood" for this fire to spread across the country. The excitement in China's stock market is certainly influenced by the chain reaction in overseas industries, but the deeper confidence stems from China's own layered layout in the brain-computer interface field.

In 2024, China had already designated brain-computer interface as one of the key areas for future industrial development. By 2025, the Ministry of Industry and Information Technology and six other departments jointly issued the "Implementation Opinions on Promoting Innovation and Development in the Brain-Computer Interface Industry." Beijing, Shanghai, and other regions have also successively introduced special action plans and billion-yuan-level industry funds.

The strong top-down push has provided fertile ground for the research, development, and transformation of technology, turning research findings from concepts停留在论文上的概念 into realities that genuinely change the lives of ordinary people.

The NEO system, co-developed by Professor Hong Bo's team from Tsinghua University School of Medicine and Neuracle, is a representative technological product in the semi-invasive field. They place flexible electrodes on the dura mater of the brain, avoiding direct penetration into the fragile brain tissue, minimizing damage while enabling effective brain-computer training.

Dong Hui, a patient who had been paralyzed from the neck down for over a decade due to a car accident, regained the ability to not only control a computer with his thoughts after being implanted with the system but also to manually grasp a water bottle with the help of a robotic arm, despite having long lost sensation in his hands. His case demonstrates that brain-computer interfaces can be more than just functional "replacements" — they may also serve as "repairers" of neural pathways.

In the invasive field that requires penetrating the dura mater, China has also made remarkable achievements that have drawn industry attention.

Shanghai's Neuracle Technology has been benchmarking against Neuralink since its inception. In clinical trials, patients using their devices can control various mechanical products through thought. In the documentary "Restart Life" released by the company, founder Tao Hu and brain-computer interface testers have even successfully competed in gaming under different operation modes.

Meanwhile, Neuracle has also made a key breakthrough in the field of language decoding. Its system has achieved high-precision real-time Chinese decoding for the first time globally. After patients with damaged brain language areas undergo surgery, the brain-computer system’s decoding accuracy rate for their commonly used Chinese syllables reaches as high as 71.5%.

As a well-known brain specialty hospital group in China, Sanbo Brain Hospital has also deeply participated in several clinical research projects on invasive brain-computer interfaces with its strong neurosurgical expertise.

Recently, his team successfully helped a patient who had a brainstem stroke achieve mind-controlled cursor typing through an implanted electrode, enabling real-time text communication with family members. According to data released by Sanbo Brain Hospital, the patient's mind-typing accuracy rate stabilized above 95% within three months post-surgery, with peak performance reaching up to 20 characters per minute.

From Musk's bold commercialization claims to China's national strategic layout, from the iteration of core technologies to paralyzed patients regaining new life, a series of phenomena clearly indicate that the industrial narrative of brain-computer interfaces has established a solid technological and policy foundation. Behind the soaring market value lies the market's strong expectation that the sci-fi concept of "practical brain-computer applications" is about to be realized.

| Capital Carnival, Hard to Conceal Development Dilemmas |

However, beneath the glare of the spotlight and the frenzy of trading halts, the development of the brain-computer interface industry also faces significant challenges that are hard to ignore.

The invasive/semi-invasive approaches represented by Neuralink and BrainCo are at the core of current technological narratives and are the most sought-after direction in the capital market. However, their essence is not consumer electronics as depicted in science fiction, but rather highly demanding high-end medical devices, whose development must adhere to strict rules within the medical field.

It is important to note that, on average, it takes 12 to 15 years for an innovative drug to progress from research and development to market availability. As a Class III medical device that needs to be implanted into the human body, the path to commercialization for brain-computer interfaces is even more protracted and costly.

Take Neuracle, a leading company in China, as an example. Although its NEO system has successfully completed more than 30 clinical trials, there is still a long way to go before it can officially obtain the Class III medical device registration certificate issued by the National Medical Products Administration. In this process, brain-computer interface devices need larger-scale, multi-center, and long-term clinical trials to verify their long-term safety, effectiveness, and stability.

The long cycle of clinical trials and the continuous increase in R&D costs have also driven up product pricing. Although some regions in China, such as Sichuan and Hubei, have already included medical service items related to brain-computer interfaces in their fee schedules, the cost of brain-computer interface surgeries remains as high as hundreds of thousands of yuan. Many ordinary patient families cannot afford it, making it difficult to achieve large-scale implementation.

And implanting electrodes into the brain, in addition to the risks associated with surgery and long-term maintenance, may also lead to ethical risks such as social equity and identity recognition. After all, brain signals represent the most fundamental level of human privacy, and once they can be read, there is a risk of being stolen, misused, or even tampered with.

However, the non-invasive approach represented by Neuracle Technology has cleverly avoided surgical risks and stringent medical regulations. With a shorter path to commercialization, it can gain market recognition more quickly. Recently, multiple media outlets reported that Neuracle Technology has completed a new round of substantial financing and is quietly advancing towards an IPO. This alone demonstrates the capital market's optimism about its development prospects.

Neuracle is indeed a global leader in the precision of non-invasive EEG signal acquisition and decoding algorithms. By 2025, the company has been granted more than 460 authorized patents. Its products, such as the intelligent bionic hand and intelligent bionic leg, have provided practical assistance to people with disabilities.

However, when the development route of brain-computer interfaces extends from the medical rehabilitation field to the broader mass consumer market, challenges will also surface.

Compared with invasive brain-computer interfaces, non-invasive consumer-grade products launched by Strong Brain Technology, such as sleep aids and focus training headbands, often face skepticism of being labeled as "IQ tax". This is because the EEG signals collected through the skull have low signal-to-noise ratio and poor resolution, and the neurological effects related to sleep and focus are difficult to quantify.

One path is to climb the "Mount Everest" of medical devices, which is long and arduous; the other is to struggle in the red ocean of consumer goods, making it difficult to quickly establish technical barriers for products. The commercialization path of brain-computer interfaces seems bustling, but in reality, regardless of the chosen direction, there are inevitable "challenges" that must be faced and resolved.

| When "Digital Immortality" Meets "Clinical Reality" |

Human-machine symbiosis, consciousness uploading, and digital immortality—the ultimate vision Musk paints for brain-computer interfaces is undoubtedly exhilarating. However, for practitioners at the cusp of industrialization, solving the most fundamental engine problem of clinical reality is the key to ensuring the future spacecraft can set sail smoothly before reaching the vast ocean of digital immortality.

The "PPT Dream-making" era in all fields of the technology sector is coming to an end. The capital market and the brain-computer interface industry are returning to rationality at an unprecedented speed. The focus of competition in the next phase will no longer be on who can tell a grander story, but on who can be the first to achieve results in the medical field and bring tangible changes to the large number of patients suffering from paralysis, ALS, and other diseases.

Before the true industrial singularity arrives, China's brain-computer interface industry still needs to navigate through three narrow gates: regulatory approval, payment capability, and market ecosystem.

In China, any device that needs to be implanted into the human bodyMedical DeviceAll must pass the strictest Class III medical device approval, and brain-computer interface devices similarly need to obtain a Class III medical device registration certificate. This "permit" is the only legal document for brain-computer interface devices to transition from experimental products to mature ones, and it is also the cornerstone for gaining market access and earning the trust of doctors and patients.

No matter how advanced a technology is, if patients cannot afford it, it still cannot generate real social value and commercial value. Therefore, to solve the core payment capability problem in commercialization, enterprises need to reduce costs through technological iteration and large-scale production, and strive to include brain-computer interface devices in the medical insurance reimbursement catalog, fulfilling the original intention of making technology accessible to all.

Of course, the successful application of brain-computer interfaces is not only about the success of the surgery; it is a complex process that spans the entire life cycle of the patient.

The winners in the future brain-computer interface sector will be ecosystem builders capable of integrating "technology-clinical-institutional" resources, thereby upgrading single-device sales into comprehensive, full-cycle medical services covering evaluation, surgery, and rehabilitation training to form a sustainable commercial closed loop.

The capital market and practitioners must clearly recognize that the road to industrial maturity for brain-computer interfaces is long and arduous. However, the strong support of national policies and the enthusiastic influx of the capital market have also injected unprecedented momentum and hope into this difficult expedition.

Image source: Internet, infringement deleted.

       Title: Stock Price Soars, Is the Commercialization Era of Brain-Computer Interfaces About to Begin?